Literature DB >> 28592535

Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells In Vitro: Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase.

Udaya S Rangaswamy1, Weijia Wang1, Xing Cheng1, Patrick McTamney2, Danielle Carroll3, Hong Jin4.   

Abstract

Newcastle disease virus (NDV) is an oncolytic virus being developed for the treatment of cancer. Following infection of a human ovarian cancer cell line (OVCAR3) with a recombinant low-pathogenic NDV, persistent infection was established in a subset of tumor cells. Persistently infected (PI) cells exhibited resistance to superinfection with NDV and established an antiviral state, as demonstrated by upregulation of interferon and interferon-induced genes such as myxoma resistance gene 1 (Mx1) and retinoic acid-inducing gene-I (RIG-I). Viruses released from PI cells induced higher cell-to-cell fusion than the parental virus following infection in two tumor cell lines tested, HT1080 and HeLa, and remained attenuated in chickens. Two mutations, one in the fusion (F) protein cleavage site, F117S (F117S), and another in hemagglutinin-neuraminidase (HN), G169R (HN169R), located in the second sialic acid binding region, were responsible for the hyperfusogenic phenotype. F117S improves F protein cleavage efficiency, facilitating cell-to-cell fusion, while HN169R possesses a multifaceted role in contributing to higher fusion, reduced receptor binding, and lower neuraminidase activity, which together result in increased fusion and reduced viral replication. Thus, establishment of persistent infection in vitro involves viral genetic changes that facilitate efficient viral spread from cell to cell as a potential mechanism to escape host antiviral responses. The results of our study also demonstrate a critical role in the viral life cycle for the second receptor binding region of the HN protein, which is conserved in several paramyxoviruses.IMPORTANCE Oncolytic Newcastle disease virus (NDV) could establish persistent infection in a tumor cell line, resulting in a steady antiviral state reflected by constitutively expressed interferon. Viruses isolated from persistently infected cells are highly fusogenic, and this phenotype has been mapped to two mutations, one each in the fusion (F) and hemagglutinin-neuraminidase (HN) proteins. The F117S mutation in the F protein cleavage site improved F protein cleavage efficiency while the HN169R mutation located at the second receptor binding site of the HN protein contributed to a complex phenotype consisting of a modest increase in fusion and cell killing, lower neuraminidase activity, and reduced viral growth. This study highlights the intricate nature of these two mutations in the glycoproteins of NDV in the establishment of persistent infection. The data also shed light on the critical balance between the F and HN proteins required for efficient NDV infection and their role in avian pathogenicity.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  NDV; Newcastle disease virus; fusion; paramyxovirus; persistent infection

Mesh:

Substances:

Year:  2017        PMID: 28592535      PMCID: PMC5533931          DOI: 10.1128/JVI.00770-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

Review 1.  Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors.

Authors:  Kenya Honda; Akinori Takaoka; Tadatsugu Taniguchi
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

2.  Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Authors:  Marlena M Westcott; Jingfang Liu; Karishma Rajani; Ralph D'Agostino; Douglas S Lyles; Mercedes Porosnicu
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

3.  Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines.

Authors:  Sateesh Krishnamurthy; Toru Takimoto; Ruth Ann Scroggs; Allen Portner
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Recombinant Sendai viruses with L1618V mutation in their L polymerase protein establish persistent infection, but not temperature sensitivity.

Authors:  Machiko Nishio; Ai Nagata; Masato Tsurudome; Morihiro Ito; Mitsuo Kawano; Hiroshi Komada; Yasuhiko Ito
Journal:  Virology       Date:  2004-11-24       Impact factor: 3.616

Review 5.  Replication-selective oncolytic viruses in the treatment of cancer.

Authors:  Bart Everts; Henk G van der Poel
Journal:  Cancer Gene Ther       Date:  2005-02       Impact factor: 5.987

6.  Activation of MDA5 requires higher-order RNA structures generated during virus infection.

Authors:  Andreas Pichlmair; Oliver Schulz; Choon-Ping Tan; Jan Rehwinkel; Hiroki Kato; Osamu Takeuchi; Shizuo Akira; Michael Way; Giampietro Schiavo; Caetano Reis e Sousa
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

7.  The properties of recombinant Sendai virus having the P gene of Sendai virus pi strain derived from BHK cells persistently infected with Sendai virus.

Authors:  Machiko Nishio; Ai Nagata; Ayako Yamamoto; Masato Tsurudome; Morihiro Ito; Mitsuo Kawano; Hiroshi Komada; Yasuhiko Ito
Journal:  Med Microbiol Immunol       Date:  2006-02-08       Impact factor: 3.402

Review 8.  Timing is everything: Fine-tuned molecular machines orchestrate paramyxovirus entry.

Authors:  Sayantan Bose; Theodore S Jardetzky; Robert A Lamb
Journal:  Virology       Date:  2015-03-12       Impact factor: 3.616

9.  Defective viral genomes arising in vivo provide critical danger signals for the triggering of lung antiviral immunity.

Authors:  Karla Tapia; Won-Keun Kim; Yan Sun; Xiomara Mercado-López; Emily Dunay; Megan Wise; Michael Adu; Carolina B López
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823

10.  Studies on persistent infections of tissue cultures. II. Nature of the resistance to vesicular stomatitis virus.

Authors:  V V BERGS; G HENLE; F DEINHARDT; W HENLE
Journal:  J Exp Med       Date:  1958-10-01       Impact factor: 14.307

View more
  8 in total

Review 1.  Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical.

Authors:  Chao Tang; Lan Li; Tong Mo; Jintong Na; Zhangbo Qian; Dianfa Fan; Xinjun Sun; Min Yao; Lina Pan; Yong Huang; Liping Zhong
Journal:  Clin Transl Oncol       Date:  2022-05-25       Impact factor: 3.340

2.  Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA-Damaging Agents: Implications for Oncolytic Virus Therapy.

Authors:  Candace R Fox; Griffith D Parks
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

Review 3.  Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.

Authors:  Volker Schirrmacher; Stefaan van Gool; Wilfried Stuecker
Journal:  Biomedicines       Date:  2019-08-30

4.  Evaluation of a Recombinant Newcastle Disease Virus Expressing Human IL12 against Human Breast Cancer.

Authors:  Zahiah Mohamed Amin; Muhamad Alhapis Che Ani; Sheau Wei Tan; Swee Keong Yeap; Noorjahan Banu Alitheen; Syed Umar Faruq Syed Najmuddin; Jeevanathan Kalyanasundram; Soon Choy Chan; Abhi Veerakumarasivam; Suet Lin Chia; Khatijah Yusoff
Journal:  Sci Rep       Date:  2019-09-30       Impact factor: 4.379

5.  Identification of a new amino acid mutation in the HN protein of NDV involved in pathogenicity.

Authors:  Xi Chen; Yanqing Jia; Ning Wei; Chao Ye; Huafang Hao; Sa Xiao; Xinglong Wang; Haijin Liu; Zengqi Yang
Journal:  Vet Res       Date:  2021-12-20       Impact factor: 3.683

6.  Optimizing environmental safety and cell-killing potential of oncolytic Newcastle Disease virus with modifications of the V, F and HN genes.

Authors:  J Fréderique de Graaf; Stefan van Nieuwkoop; Theo Bestebroer; Daphne Groeneveld; Casper H J van Eijck; Ron A M Fouchier; Bernadette G van den Hoogen
Journal:  PLoS One       Date:  2022-02-09       Impact factor: 3.240

Review 7.  Syncytia Formation in Oncolytic Virotherapy.

Authors:  Chase Burton; Eric Bartee
Journal:  Mol Ther Oncolytics       Date:  2019-10-01       Impact factor: 7.200

8.  Optimization of oncolytic effect of Newcastle disease virus Clone30 by selecting sensitive tumor host and constructing more oncolytic viruses.

Authors:  Tianyan Liu; Yu Zhang; Yukai Cao; Shan Jiang; Rui Sun; Jiechao Yin; Zhenqiu Gao; Guiping Ren; Zhenzhong Wang; Qingzhong Yu; Guangchao Sui; Xu Sun; Wenying Sun; Wei Xiao; Deshan Li
Journal:  Gene Ther       Date:  2020-05-14       Impact factor: 5.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.